We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

172 hedge funds and large institutions have $2.79B invested in Ultragenyx Pharmaceutical in 2016 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 67 increasing their positions, 56 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more call options, than puts

Call options by funds: $14.3M | Put options by funds: $6.15M

80% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 15

54% more capital invested

Capital invested by funds: $1.81B → $2.79B (+$978M)

20% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 56

7% more funds holding

Funds holding: 161 → 172 (+11)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
172
Holders Change
+11
Holders Change %
+6.83%
% of All Funds
4.59%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
27
Increased
67
Reduced
56
Closed
15
Calls
$14.3M
Puts
$6.15M
Net Calls
+$8.14M
Net Calls Change
+$9.02M

Top Buyers

1
CGT
Capital Guardian Trust
California
+$31.5M
2
Capital International Investors
Capital International Investors
California
+$30.7M
3
CWAM
Columbia Wanger Asset Management
Illinois
+$25.1M
4
EA
Emerald Advisers
Pennsylvania
+$17.2M
5
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
+$16.9M

Top Sellers

1
Wells Fargo
Wells Fargo
California
-$39.1M
2
Millennium Management
Millennium Management
New York
-$28.8M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$11.5M
4
Ameriprise
Ameriprise
Minnesota
-$11.2M
5
WC
Weatherbie Capital
Massachusetts
-$6.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$20M +$1.16M +18,212 +7%
Brown Advisory
27
Brown Advisory
Maryland
$20M +$1.26M +19,790 +8%
Geode Capital Management
28
Geode Capital Management
Massachusetts
$19.5M +$703K +11,018 +4%
EA
29
Emerald Advisers
Pennsylvania
$19.2M +$17.2M +269,983 New
EMFAT
30
Emerald Mutual Fund Advisers Trust
Pennsylvania
$18.8M +$16.9M +264,546 New
PC
31
Polar Capital
United Kingdom
$17.1M +$15.1M +236,803 +4,816%
Axa
32
Axa
France
$16.6M +$406K +6,356 +3%
WC
33
Weatherbie Capital
Massachusetts
$16.4M -$6.84M -107,160 -32%
Deutsche Bank
34
Deutsche Bank
Germany
$15.2M +$3.56M +55,799 +35%
Charles Schwab
35
Charles Schwab
California
$13.1M +$868K +13,606 +8%
Ameriprise
36
Ameriprise
Minnesota
$12.3M -$11.2M -175,434 -50%
TA
37
Teachers Advisors
New York
$12.3M +$32.6K +510 +0.3%
O
38
OrbiMed
New York
$12M – – –
Bank of New York Mellon
39
Bank of New York Mellon
New York
$11.7M -$419K -6,560 -4%
CCI
40
Columbus Circle Investors
$11.6M -$1.45M -22,784 -12%
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$11.5M +$1.81M +28,314 +21%
Lord, Abbett & Co
42
Lord, Abbett & Co
New Jersey
$11.2M -$11.5M -179,977 -53%
CI
43
Capital International
California
$11.1M +$10M +157,000 New
Invesco
44
Invesco
Georgia
$11.1M +$10M +156,924 New
BIM
45
BlackRock Investment Management
Delaware
$10.9M +$54K +846 +0.6%
RSCM
46
Rock Springs Capital Management
Maryland
$10.4M +$351K +5,500 +4%
CS
47
Credit Suisse
Switzerland
$8.47M -$1.39M -21,811 -15%
CAM
48
Cormorant Asset Management
Massachusetts
$7.86M – – –
HRCM
49
Hood River Capital Management
Florida
$7.82M +$7.04M +110,291 New
BBA
50
Baker Bros. Advisors
New York
$7.09M -$695K -10,894 -10%
1
2
3 4 5

RARE Hedge Fund Activity: Q3 2016 in Review

172 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q3 2016, worth a combined $2.79B — up 54% from $1.81B a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new RARE positions and 15 closed out — a net gain of 12 holders — while 67 added to existing stakes and 56 trimmed.

The largest buyer was Capital Guardian Trust, opening a new position worth an estimated $31.5M. The largest seller was Wells Fargo, cutting an estimated $39.1M.

  • 172 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q3 2016, up from 161 in Q2 2016.
  • Funds reported $2.79B of Ultragenyx Pharmaceutical stock for Q3 2016, up 54% quarter-over-quarter.
  • 27 funds opened new Ultragenyx Pharmaceutical positions in Q3 2016 and 15 closed out, a net change of +12 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q3 2016 was Capital Guardian Trust, an estimated $31.5M added.
  • The largest Ultragenyx Pharmaceutical seller in Q3 2016 was Wells Fargo, an estimated $39.1M sold.

Based on aggregated 13F filings for Q3 2016.